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The majority of patients with metastatic germ cell tumors can 
be cured with currently available poly-chemotherapy. Based 
on presenting criteria three prognostic groups can be dis­
cerned. In patients with a good prognosis (> 90% probability 
of 5-year survival) attempts have been made to diminish 
the dose of the active compounds in the BEP regimen. The 
omission of bleomycin cannot be recommended on pres­
ently available data; and a total dose of at least 240 mg seems 
appropriate. Platinum at a dose intensity below 75 mg/m2/ 
3 weeks compromised efficacy and the recommended dose 
is 100 mg/m2. A true comparison between the two most 
frequently used etoposide doses has not been performed. 
Based on the available literature etoposide should be given 
In doses of at least 360 mg/m2/cycle when four courses are 
given and 500 mg/m2/cycle when three courses are given. 
For intermediate and high-risk patients alternating, acceler­
ated and high-dose chemotherapy can be considered. None 
of the alternating and accelerated regimens has a proven 
advantage in randomized trials and they remain investiga­
tional. The addition of hematopoietic growth factors permits 
a higher dose intensity of BEP/EP and BOP/VIP; although to 
date there is no proven impact on outcome. The application 
of high-dose chemotherapy for one to four courses Is feasi­
ble with the support of both hematopoietic growth factors 
and autologous bone marrow or peripheral stem cells. In true 
chemotherapy-resistant disease the value of this approach 
seems limited. Its role In patients with a first relapse should 
be further explored. The approach of high-dose chemother­
apy in first line for patients with poor prognostic features 
should preferentially be investigated In a randomized fash­
ion, but this will require extensive international collabora­
tion in view of the low incidence and the expected advantage 
of the approach.
Introduction
The d ev e lo p m en t of the trea tm ent o f  germ  cell tu ­
mors is a classic story in the m odern  era o f  c h e m o ­
therapy  and  m any lessons can be lea rned  from  it.
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Since the in troduction  of cisplatin CP) 1 major progress 
has been  m ade , the m ajority  of patien ts  now  ob ta in ­
ing cure  ev en  w ith  far adv an ced  m etastatic disease, 
At the  m om en t several active drugs are identified 
for this d isease: cisplatin , b leom ycin , vinblastine, 
e toposide , ifosfam ide, carbopla tin , cy c lo p h o sp h a­
mide; to a lesser ex ten t adriam ycin  and  actino- 
mycin-d; and  m ore recen tly  p ac litaxe l .2 The first 
b reak th rough  cam e from  the com bina tion  o f cis­
platin, v inblastine (0.4 m g /kg ) and  b leom ycin  given 
q 3 w eek s  x 4 fo llow ed  by 21 m on ths vinblastine 
m ain tenance  therapy , From  this early  experience  it 
also becam e c lear that add itional courses after four 
courses of PVB (cisplatin, v inblastine, b leom ycin) 
w ere  clinically no t induc ing  m ore com plete  rem is­
s io n s .3 This ind ica ted  that a h igher total dose  of 
these drugs d id  not con tribu te  and  the s tandard  
num ber w as estab lished  to  be four, The total dose  
of v inblastine  in this s tudy  w as high and  contribu ted  
significantly to the o b se rv ed  toxicity. In a su b se ­
q u en t study the h igher d o se  of v inblastine (0.4 vs 
0.3 m g /kg ) resu lted  in sim ilar th e rap eu tic  efficacy .'1 
The n u m b er of patien ts  trea ted  in this study (26 vs 
27) was low and  therefore  does no t m eet the stat­
istical criteria for equ iva lence  in ou tcom e. It result­
ed, how ever, in the  es tab lishm en t of the reduced  
vinblastine do se  as the s tandard , In an o th e r  ran­
dom ized study  om ission  o f the m ain tenance  treat­
m ent with v inblastine  w as also sh o w n  not to com ­
prom ise o u tc o m e .1’ T hese  s tud ies  w ere  am ong  the 
first to look at do se  in tensity  and  total dose  given in 
re la tion  to tre a tm e n t o u tco m e . T he su b se q u e n t 
discovery of e to p o s id e  as an active agen t with a 
different toxicity profile  led to the d ev e lo p m en t of 
the BEP (b leom ycin , e to p o s id e , cisplatin) com bina­
tion and  this is the b a c k b o n e  of p re sen t ch em o th er­
apy  for m etasta tic  germ  cell tu m o rs /1"” This therapy  
results in the cure o f  app rox im ate ly  70%-H0% of 
patients. Factors assoc ia ted  with treatm ent failure 
have been  ana lyzed  in several large studies and
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in c lu d e  large tu m o r vo lum e, the  p resen ce  of liver, tients w ere  characterized  by lym ph n o d es  < 5 cm, 
b o n e  o r  b ra in  m é tas ta sés , grossly e leva ted  tum or lung m etastasis < 2 cm, a Ipha-foe to p ro te in  (AFP)
< 1000 ng/m l, hum an  chorion ic  gonado tro fin  (HCG)
< 10,000 IU/1. T oday  th e  cu t-off va lues  for the
m arkers , and  an e x tra g o n a d a l prim ary  site, particu ­
larly in the  m e d ia s t in u m .y~15 B ased  on  these  p ro g ­
nostic  factors clin ical trials have  investigated  e ither m arkers are still valid, b u t m ore  recen t p rognostic  
d e c re a s in g  d o se s  to  d im in ish  the toxicity of the factor analyses have sh o w n  that patien ts  w ith  m ore 
s ta n d a rd  o f  fou r BEP cycles in patients w ith  good- extensive m étastasés can  still be ca tegorized  as 
risk d isea se  (p re d ic te d  cu re  rate  > 90%), o r  im prov- having a g o o d  prognosis . W ith 393 pa tien ts  en te red  
ing  the resu lts  by in tensify ing  therapy  in  patients into the study, 97% of the  evaluab le  pa tien ts  receiv- 
w ith  in te rm ed ia te -r isk  (p red ic ted  cure ra te  80%) ing BEP and  91% o f pa tien ts  receiv ing  EP ach ieved
a n d  p o o r-r isk  (p re d ic te d  cure rate 50%) disease. com plete  rem ission, O f the com ple te  re sp o n d ers ,
S tud ies o f  d o se  a n d  re sp o n se  in germ  cell tu- 6 receiving EP and 7 receiv ing  BEP re lapsed . Al- 
m ours  a re  n o t  e x te n s iv e  and  p rov ide  only  limited though there w as no  statistical d ifference b e tw een  
e v id e n c e  to  s u p p o r t  th e  d o s e - r e s p o n s e  m odel, the two arm s a few  m ore  patien ts  p ro g ressed  and
died on the  EP arm , ev en  th o u g h  the eligibility 
criteria actually se lec ted  for ultra-good, p rognostic
S ch ed u le  d e p e n d e n c y  is qu ite  often  ignored  in this 
co n tex t, as is sy n e rg y  b e tw e e n  d ru g s .16 In studies 
ap p ly in g  a lte rn a tin g  th e ra p e u tic  agents it is im por- patients. The n u m b er  o f  even ts in this s tudy  is low 
tan t tha t active  c o m p o u n d s  w ith  a d ifferen t m e d ia -  and  the study  therefore  lacks the p o w e r  to give a 
n ism  o f ac tio n  are  u sed , It is against this b ack g ro u n d  final answ er. At the sam e tim e an ECOG p rospec tive
tha t the  p re se n tly  ava ilab le  literature sh o u ld  be 
assessed .
Chemotherapy in good-risk disease
random ized  study com paring  three courses o f  BEP 
(e toposide  500 m g /m 2/cyc le) w ith th ree  cou rses  of 
EP in patien ts  w ith  m inim al or in term ed ia te  d isease  
by the Ind iana  classification sh o w ed  p rogress ion - 
free survival of only  69% in the patien ts  using  the 
tw o-drug schedu le  co m p ared  to 85% w ith  th ree  
As m e n tio n e d  a b o v e , clinical trials in patien ts  w ith d ru g s .18 It is im portan t to realize that the  Ind iana 
a h igh  p ro b a b ili ty  o f  c u re  have focused  o n  decreas- goocl-prognosis g roup  also com prises pa tien ts  of 
ing the tox ic ity  o f  s ta n d a rd  c h e m o th e ra p y .2,17 At the in term ediate  g ro u p  accord ing  to the  EORTC 
p re sen t a 5-day  re g im e n  o f BEP is co n s id e red  the classification. It is obv ious that b leom ycin  can n o t be 
“gold  s ta n d a rd ”, u su a lly  ad m in is te red  3-w eekly  for om itted  w h en  th ree  courses of ch em o th e rap y  are 
a total o f  fo u r  cycles. D uring  the  past d ecad e  efforts given. W hen  four cou rses  are delivered  o n e  could  
to w ard s  d e c re a s in g  tox ic ity  h av e  included: ( ! )  de- consider d im in ish ing  the  dose  of b leom ycin . I iow - 
fin ing  th e  ro le  o f  full-close b leom ycin  (w ith  well ever, based  on the data p resen tly  available a true 
k n o w n  tox icities  in c lu d in g  R aynaud’s p h e n o m e n o n  threshold  canno t be  given, 
and  p u lm o n a ry  fibrosis); (2 ) decreasing  th e  dose  of
e to p o s id e  p e r  cycle; (3 ) d ec reas in g  the du ra tion  of 
th e rap y  (n u m b e r  o f  cycles and  n u m b er o f  days p e r Duration of therapy
cycle); a n d  (4) re d u c in g  toxicity  by rep lacem en t of The South Eastern C ancer Study G roup  (SECSG) in-
c isp la tin  by c a rb o p la tin  ( w h ich  is less em etogen ic , 
n eu ro to x ic  and  n e p h ro to x ic ) .  A p p ro ach es  (1 )—(3 ) 
a re  re la ted  to d o se  in tensity  an d  total d o se  in the 
trea tm en t of this d isease .
Bleomycin
vestigatecl w hether, in those  with g o o d -p ro g no sis  
NSGCC, th ree  courses o f  BEP was equ iva len t to the 
standard  four-courses re g im e n .19 T he trial w as d e ­
signed to show  a < 10% difference in the resp o n se  
rate for three courses co m p ared  with four courses. 
O ne h u n d red  and e ighty-four patien ts  en te red  the 
study. Eighty-six o f  88 pa tien ts  (98%) random ized
T he  ro le  o f  b leo m y c in  in the m a n ag em en t of non- to three courses, and  93 of 96 random ized  to four
se m in o m a to u s  g e rm  cell can cer (NSGCC) has b e en  courses (97%) of BEP ach ieved  d isease-free  status,
th e  su b je c t  o f  s e v e ra l  ra n d o m iz e d  stud ies. T he There w ere  10 re lapses (5%), five on  each arm. After
EORTC d irec tly  c o m p a re d  four cycles of BEP (e top - a m edian  fo llow -up of only  19 m onths (range 13-30
o s id e  360 m g /m 2/c y c le )  w ith  four cycles of EP 
(e to p o s id e ,  c isp la tin )  in  p a tien ts  d e e m e d  to be
m onths) 81 of 88 (92%) an d  88 of 96 (92%) patients 
random ized  to three vs folir courses of BEP w ere  
g o o d -r isk  by the  crite ria  o f  th e  EORTC. This trial free of d isease. T he au tho rs  repo rted  that th ree  
s ta r ted  in 1982. At tha t tim e th e  EORTC p rognostic  courses of BEP cou ld  be reg a rd ed  as s tan d ard  
fac to r analysis  in d ic a te d  that g o o d -p ro g n o sis  pa- treatm ent for favorab le-prognosis  NSGCC.
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Germ cell tumors
It has since b ee n  q u es tio n ed  w h e th e r  this trial In a series of 127 pa tien ts  [Vom the MRC with meta-
of only ‘184 patien ts  had  p rov ided  suffic ien t data to 
conclude  that three BEP equals  four BEP as far as
static germ  cell cancer w h o  had  b e e n  treated  with 
four BEP cycles consisting  of c isplatin  20 m g /m 2 
progression-free survival and  survival a re  concerned . per day on  days 1- 5 , e to p o s id e  120 m g /m 2 per day
A lthough the sam ple  size w as sufficient to  detect a 
10% difference at a p o w e r  of 85%, it d id  n o t allow
on days 1- 3 , a n d  b leom ycin  30 mg on days 2 , 9 and  
16, a w hite  cell coun t nad ir  of < 1.0 x 10‘7 1 occurred  
the d e tec tio n  of a clinically m ean ingfu l d ifference in on ly  2% o f  482 c o u r s e s .7 T h e re  w ere  th ree  
b e tw een  5% a n d  9%. Of equa l im p o rtan ce  w as tha t ep isodes of n eu tro p en ic  sepsis, w ith one death  in 
the m ed ian  fo llow -up  of 19 m onths is p robab ly  no t a pa tien t w h o  had  rece ived  additional h igh-dose 
sufficient to  m ake the result of this s tu d y  definitive. m etho trexate  for poorly  resp o n d in g  bulky disease. 
There has b ee n  no form al u p d a te  s ince  (personal Significant th ro m b o cy to p en ia  w as rarely seen  and 
com m unication , P. Loehrer, study coo rd ina to r, 16 p latelet coun ts  < 50,000 x 10 'Yl occurred  in 2% of
May 1994), In E urope th ree  cycles are therefo re  no t 
generally  accep ted  as the  standard  treatm ent. In 
a d isease  w h e re  cure can  b e  ach ieved  in over 90%
482 courses. E ighteen  patien ts  h ad  treatm ent delays 
of m ore  than  2 w eeks b e tw ee n  the start of chem o­
therapy  and  the e x p e c te d  date  of com ple tion  of the
of pa tien ts  a d ifference of 5%-9% is n o t  accep tab le  fourth  course  o f  therapy . D elays occurred  p redom -
and it is genera lly  ag reed  that a n e w  trial should  
be carried  ou t to rule ou t a > 5% difference in 
p rogression-free  survival, w ith  sufficient follow -up, 
In March 1995 the MRC and  EORTC em b a rk e d  on  a
inanl'ly in the  earlier part o f the series (1979-1983) 
w h en  ch em o th e rap y  w as w ithheld  w ith total w hite 
cell coun ts  < 2.5 x lOVL The investigators reported  
that there  w as no  re la tionsh ip  b e tw een  these short
large ran d om ized  trial that is des igned  as an  equiv- treatm ent delays and stage of d isease  and  no effect 
a lence study  com paring  four vs th ree  cycles of BEP on recu rrence  or survival w as apparen t; the actual'- 
in m ore than  700 patients, w h ich  en ab le s  exclusion  ial 5-year recu rren ce -free  survival w as 79% for
of a sm all bu t m eaningfu l difference.
Etoposide dose
Finally, the  d o se  of e to p o s id e  in the  BEP regim en 
rem ains sub ject to discussion. W hereas  investiga­
tors in E urope have u sed  e to p o s id e  120 m g /m 2, 
days 1, 2, 3 (MRC) or 1, 3, 5 (EORTC), in  the US 
100 m g /m r p e r  day, days 1-5  has a lw ays been  the 
preferred  schedu le . No stud ies have ad d ressed  th e  
issue of the optim al do se  of e to p o s id e  p e r  cycle in 
a com parative  fashion.
Cisplatin vs carboplatin
no delay  co m p ared  to 85% for delay  > 1 w eek. It 
shou ld  be em p h as ized  that the n u m b er of patients 
at risk was low  (18) a n d  therefo re  this observation , 
though  reassuring , do es  no t constitu te  scientific 
proof.
W hen a 5-day sch ed u le  o f  e to p o s id e  100 m g /m 2 
per day is used, the  inc idence  of grade 3/4 leuko- 
cy topenia and  n eu tro p en ia  is m ore frequent, res­
ulting in a w hite  cell nad ir < 1.0 x 10*71 in 20% and  
incidence of fever during  n eu tro p en ia  in 15% of 
patients at som e time during  treatm ent. In a series 
of 123 patien ts  treated  at Ind iana  University over 
50%i of pa tien ts  had an abso lu te  neu troph il coun t 
< 0 .5  x KV71 at som e tim e d u rin g  trea tm en t .22 Tw o
The role o f  carbop la tin  as rep lacem en t for cisplatin  patients d ied  o f  sepsis w hile  they  had neu tropen ia ,
is b ey o n d  the scope  of this rev iew  and will therefo re  
not be d iscussed  in detail. Based on  th e  available 
data cisplatin  shou ld  be the drug of c h o ic e .20,21
Fourteen p e r  cent of patien ts  had  a p latelet coun t 
<50,000 x 10VI at som e time during  treatm ent. In 
the p rev iously -m en tioned  study o f 184 patien ts  w ho 
received e ither three or four BEP cycles, one  patient 
died from ch em o th erap y -re la ted  se p s is . 19 As it ap- 
c o n s id e red  the go ld  s ta n d a rd  c h e m o th e ra p y  in pears from this latter s tudy  that the efficacy of three
In view  of the fact that four courses o f  BEP is to be
patients w ith good-risk  germ  cell tum ors, the q u e s ­
tion arises w h e th e r  the in ten d ed  dose  an d  schedu le
BEP cycles is no t clearly inferior to four cycles, this 
w ould  lend su p p o r t  to the conc lu s ion  that m inor
of BEP shou ld  be m ain ta ined  v igo rously  if fou r dose  m odifications or so m e  delay  in a s tandard  reg- 
cycles are being  given. In genera l d rug  d o se  ad her- imen of BEP courses  are no t critical, as long as four 
ence will be reg a rd ed  as critical if a tw o -d ru g  cycles are be ing  adm in is te red .
regim en or only th ree  cycles of BEP are  b e in g  given, 
It is h o w ev e r  unlikely  that a 25% do se  reduc tion  o f
At the M em orial S loan-K ettering C ancer Center 
(MSKCC) the effect of d u ra tio n  of induction  ther-
e to p o s id e  a n d /o r  cisplatin  for o n e  or tw o  cycles will apy on  com ple te  rem ission  (CR) rate and disease- 
com prom ise  trea tm ent ou tcom e in th e  case of a free survival (DES) w as eva lua ted  by m eans of un i­
p lanned  full-dose BEP reg im en  over four courses. variate and  m ultivariate  regression  analyses in 162
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goocl-risk p a tien ts  t re a te d  w ith  e ith e r  VAB-6 (vin- Drug com bina tions  in seq u en ce  have b een  ex-
b lastine , b leo m y c in , ac tinom ycin -D , cy c lo p h o sp h a- p lo red  at the  C haring Cross H ospital w ith  POM1V
micle, c isp la tin )  at 28-day  in tervals for th ree  cycles ACE ch em o th erap y  (cisplatin , vincristine, metlio-
o r fou r cycles o f  EP a t 21-day  in te rva ls .2* T rea tm en t trexate, b leom ycin /ac tinom ycin -D , cyc lophospha-
w as ro u tin e ly  p o s tp o n e d  for 7 days for leukocy tes  micle, e toposide). Recently, an  u p d a te d  analysis
< 3*0 x 109/1 o r  p la te le ts  < 100 x 109/1 on th e  day o f  w as published  co n cern in g  206 pa tien ts  trea ted  be-
p la n n e d  tre a tm e n t a n d  th e ra p y  w as then  ad min is- tw een  1977 a n d  1988 .26 In a fu rther s tudy  106 out
te red  re g a rd le ss  o f  b lo o d  coun t. The p ro p o rtio n  of of 193 fully evaluab le  pa tien ts  had  large-volum e
CR an d  DFS w e re  n o t  in f lu en ced  by a ^  7-day delay  m etastatic d isease (acco rd in g  to the Royal M arsden
resu ltin g  from  c h e m o th e ra p y - in d u c e d  m yelo sup - Hospital stag ing  classification), i.e. Stage IIC (lym ph
p ress io n . T he  a u th o rs  c o n c lu d e d  that short, p lan n ed  node  m étastasés > 5 cm ) o r  L3 (lung  m étastasés > 2
de lays  in  c h e m o th e ra p y  fo r good-risk  patien ts  of s  7 cm). These 106 patien ts  w ith  ad v an ced  d isease  had
clays p e r  cycle  d id  n o t  co m p ro m ise  trea tm en t out- an overall survival o f  a lm ost 80%, The efficacy o f  the
co m e  a n d  th e re fo re  a p p e a r  accep tab le  since  they POMB/ACE reg im ens w as confirm ed  in a series of
m ay  p re v e n t  se r io u s  tox ic ity  in this cu rab le  patien t 60 patients w ith  large or very-large vo lum e m etas-
p o p u la t io n .
In c o n c lu s io n , fo u r  cycles o f  BEP is at the m o ­
m e n t c o n s id e re d  to  b e  th e  go ld  s tand ard  ch em o ­
th e rap y  in  p a tie n ts  w ith  g o o d -r isk  germ  cell cancer. 
M inor d o se  m o d if ic a tio n s  or som e delay  do no t
tases (accord ing  to the Royal M arsden  H ospital 
staging classification), resu lting  in a 5-year survival 
rate of abou t 70%.27 In one  N orth  A m erican study  48 
patients w ith advanced  d isease  (accord ing  to M.D. 
A nderson criteria) trea ted  w ith  a com bin a tio n  of
a p p e a r  to  b e  critical, as lo n g  as fo u r cycles are be ing  cyc lophospham ide , d o x o ru b ic in  and  cisplatin  ( CIS- 
g iven. V aria tions  in th e  to ta l d o se  o f  b leom ycin  over CA), and a lte rna ted  w ith  a com b ina tion  o f  vinblas-
fo u r  c o u rse s  m ay  ra n g e  from  270 to 360 mg. For 
e to p o s id e  th ese  figu res  a re  1440-2000 m g /m 2. Cis­
p la tin  in all th e se  re g im e n s  is g iven  at full dose, 400 
m g /m 2.
Intermediate- and poor-prognosis disease
For this p a t ie n t  g ro u p  trea tm en t stra teg ies include 
the  use of: ( 1 ) a l te rn a tin g  com bina tions o f  differ-
tine and b leom ycin  (VB), 44 patien ts  (92%) ach ieved  
a CR and  an 85% d u rab le  CR rate w as ach iev ed  in 
a series of 100 p a tie n ts .28 A nd in a n o th e r  s tudy  a 6- 
m on th  sch ed u le  o f  a lte rnating  cycles o f  EP and 
VAB-6 in 41 poor-risk  pa tien ts  (p red ic ted  survival 
rate < 50%) resu lted  in a d u rab le  overall CR of 
37%.29 The response  and survival o f  these  patients 
w as found to b e  identical to the results o f  29 h is­
torical contro ls  w ith poor-risk  germ  cell tum ors 
treated  with VAB-6 a lone  at the MSKCC. Based
en t reg im ens; ( 2 ) p ro to c o ls  w ith  shorter intervals on  these data this a lte rnating  w as not fu rther ex- 
o f  s ta n d a rd  d o s e s  b e tw e e n  tre a tm e n t cycles to 
in tensify  th e ra p y  (acce le ra tin g  ch em o th erap y ); an d  
( 3) in c re a se d  d o s a g e s  o f  the  indiv idual cytotoxic these alternating  regim es as the stud ies w ere  not
random ized  and  different p rognostic  se lection  cri-
It is im possib le  to judge the relative m erits of
teria w ere  used. In 1982 the EORTC b eg an  a ran­
dom ized  study co m p arin g  four cycles of BEP vs an 
alternating  regim e o f  PVB and BEP for a total o f four 
T he  ra tio n a le  for a lte rn a tin g  d ifferen t ch em o th er-  cycles for patients w ith T iigh-volum e’ m étastasés
Alternating and accelerated chemotherapy
ap y  c o m b in a tio n s  is b a sed  on th e  assum ption  that 
a tu m o r co n ta in s  cell p o p u la t io n s  that are sensitive 
to o n e  d ru g  b u t re s is tan t to a n o th e r  agent. Such 
h e te ro g e n e ity  m ay e i th e r  exist at the initiation of
(defined  as lym ph n o d e  m étastasés > 5 cm or lung 
m étastasés > 2 cm in d iam e te r ).*0 Tw o h u n d red  and 
thirty-four eligible pa tien ts  w ere  random ized . The 
CR rates to PVB/BEP an d  BEP w ere  similar: 76% and
cy tosta tic  trea tm en t, o r  d e v e lo p  du ring  trea tm ent as 72%), respectively  ( p ~  0.58). In add ition , there  w ere
a resu lt o f  b io ch em ica l m o d u la tio n  o r  genetic  m u- no  significant d ifferences in re lapse  rate, d isease- 
ta t io n ,24,25 In the  ca se  o f  germ  cell cancer it is likely free and overall survival at an  average  fo llow -up  of 
tha t na tu ra l re s is tan ce  is involved since these  tu- 6 years. The 5-year p rog ress ion -free  and survival
m ors p ro life ra te  rap id ly  a n d  the  du ra tion  o f  in d u c ­
tion  c h e m o th e ra p y  is res tr ic ted  to 3 or 4 m onths.
rates in bo th  trea tm en t g ro u p s  w ere  approx im ate ly  
80%). In '1990 the MRC/EORTC initiated a random - 
T h e se  c o n s id e ra t io n s  favo r the a p p ro a c h  w ith  alter- ized  trial co m p arin g  s ta n d a rd  th e ra p y  w ith  six
n a tin g  c h e m o th e ra p y  as the initial trea tm en t in 
p a tien ts  w ith  p o o r -p ro g n o s is  g e rm  cell tum ors.
cycles of b leom ycin  30 m g w eek ly  x 12, e to p o s id e  
100 m g /m 2 days 1—5 and cisplatin  20 m g /m 2 days
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Germ, cell tumors
1-5 (BEP/EP) given 3-weekly, against three cycles 
of b leom ycin  30 mg, vincristine 2 mg and cisplatin 
50 m g /m 2 days 1 and  2 (BOP) given every 10 days, 
follow ed by three cycles of e toposide  100 m g /m 2 
days 1, 3, 5, ifosfam ide 1 g /m 2 days 1-5 and cisplatin 
20 m g /m 2 days 1-5 (VIP) given 3-weekly in patients 
w ith  poo r-p ro g no sis  germ  cell cancer .31 The BOP/ 
VIP schedu le  incorporates  rapid  induction, i.e. a 
form  o f acce le ra ted  ch em o th e rap y  fo llow ed by 
poten tia lly  non-cross resistant chem otherapy, and 
had  prev iously  b e e n  tested  in a pilot study in 91 
cases .32 B etw een  January  1990 and  June '1994, 380 
patien ts  w ere  random ized . Eligible patients had  one 
or m ore of the following: liver/bone or brain m étas­
tasés; ßHCG * 10,000 IU/1 or AFP ;> 1000 Ku/1; lung 
m étastasés s: 20 ; lym ph n o d e  mass a  10 cm maxi­
m um  d iam eter be low  or & 5 cm above the dia­
phragm . Tw o h u n d re d  and  tw enty-eight of the 229 
patien ts  (150 on  BEP, 149 on BOP/VIP) for w hom  
data are available are evaluable for response to 
date. O f these, 68/116 (59%) on  BEP and 65/112 
(58%) on BOP/VIP ach ieved  CR. With a m edian 
fo llow -up o f  alm ost 1.5 years, 46/175 (26%) on BEP 
and  57/173 (33%) on BOP/VIP have progressed  or 
d ied  Cp = 0.15). A m ong the patients w ho achieved 
CR, 10/68 (15%) on BEP and  7/65 (11%) on BOP/ 
VIP have p rog ressed  o r  d ied  (p  = 0.73). There w ere 
a total of 14 deaths a ttribu ted  to toxicity, 6 on BEP 
and  8 on  BOP/VIP. This prelim inary analysis sug­
gests no advan tage  to the alternating and  more 
intensive schedule , a lthough  longer follow-up is 
required . In a sub g ro u p  of 263 patients, a second 
random ization  w as perfo rm ed  in o rder to investi­
gate w h e th e r  the schedu led  dose or e ither BOP/VIP 
or BEP/EP cou ld  be be tte r  m aintained with the 
add ition  of g ranu locy te-co lony  stimulating factor 
(G-CSF). A p re lim in a ry  analysis  in d ica ted  that 
10% be tte r  dose  ad h eren ce  w as achieved with the 
add ition  of G-CSF, b u t that the better dose adher­
ence d id  n o t result in a significant im provem ent of 
p rogression-free  survival (69% vs 68%) or overall 
survival (76% vs 80%), no  G-CSF vs plus G-CSF res­
pec tive ly .33
The m ain exp lana tion  for a lack of benefit from 
these ch em o th erap y  com binations may be that cis­
platin resistance is the  crucial factor for treatm ent 
failure in testicular cancer, and  that alternating vin­
b lastine an d  e toposide  or e toposide  and  ifosfamide 
will n o t have a substan tia l im pact on the efficacy of 
these co m b in a tio n s .34 Agents w ith  m ore im portant 
activity in refractory d isease  such as the  taxanes are 
alternative cand idates for drug com binations which 
m ay m erit fu rther testing  of alternating chem o­
th e ra p y .2 A lthough treatm ent w ith  BEP remains the
gold-standard therapy, random ized com parative 
trials with other schedules, given in either an alter­
nating or a sequential fashion, w ith  or w ithout an  
intensive induction phase, are justified.
increased dose per cycle
The rationale for the use of dose-intensified chem o­
therapy in intermediate- and poor-risk patients is 
based  on preclinical evidence of a d ose-resp o n se  
relationship. Because of dramatically im proved  res­
ponse rates and survival with the  in troduction of 
cisplatin into combination chem otherapy regimens, 
escalation of cisplatin dose was one of the  first 
attempts m ade to further improve clinical results.
The South W estern Oncology Group (SWOG) 
conducted  a random ized study with PVB at a cis­
platin dose of either 120 m g/m 2 every 4 w eeks or 
cisplatin 75 m g/m 2 every 4 w eek s .35 There was a 
significant increase in the com plete response  rate 
and survival for patients in the cisplatin 120 m g /m 2 
arm. The clinical meaning of cisplatin dose intensity 
in this trial was ham pered by the relatively low  dose 
intensity of cisplatin in the 75 m g/m 2 arm of 0.58 
com pared to standard BEP. The relevance o f  this 
study is that it underlines the im portance of m ain­
taining the standard cisplatin dose intensity an d  that 
reduction to 75 m g/m 2 has a detrim ental effect on  
treatm ent outcome.
The apparent improvement o f  increased-dose 
cisplatin was accentuated by a study perform ed by 
the National Cancer Institute (NCI) that w as d e ­
signed to determine w hether superior results could 
be obtained by maximum doses of chem otherapy  
comprising cisplatin 200 m g/m 2, e toposide 500 m g / 
m 2, vinblastine 0.2 m g/kg per cycle every 3 w eeks, 
and bleomycin 30 mg weekly, relative to a standard  
schem e of PVB, i.e. cisplatin 100 m g /m 2, vinblastine 
0.3 m g/kg every 3 weeks and bleom ycin 30 mg 
w eekly .36 Of the patients random ized to the high- 
dose arm, 88% obtained disease-free status com ­
pared  to 67% in the standard arm. This study has 
frequently been cited to advocate the im portance of 
cisplatin dose intensity in poor-risk germ  cell can­
cer, but the results should be in terpreted  cautiously 
since the addition of full-dose e toposide  w as the 
other variable in the high-dose cisplatin regimen.
These studies were accom panied or follow ed by 
a num ber of phase II trials that invariably reported  
superior outcom e but as m entioned  earlier are dif­
ficult to interpret since a myriad of classification 
systems to assign poor risk w ere  a p p lie d .27,28,37 
Trials have included patients that by o ther classifi­
cation systems w ould be regarded as good-risk,
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p a rticu la rly  in  te rm s  o f  the n u m b e r  of p u lm o n ary  
m é ta s ta sé s  a n d  th e  s ize  of ab d o m in a l lesions.
O n e  im p o r ta n t  ra n d o m iz e d  clinical trial o f cis­
p la tin  d o se  in ten s ity  w a s  p e rfo rm ed  by the SECSG 
a n d  S’W O G .38 T h is  s tu d y  co m p ared  the efficacy of 
BEP at e i th e r  a c isp la tin  d o se  o f  100 m g /m 2 p e r  cycle
limiting toxicities w e re  m ucositis and p ro lo n g ed  
t h 1*0 m bo  cy t: o p e n i a .
No random ized  data are availab le  to da te  com ­
paring  s tan d a rd  BEP o r ifosfam ide-con ta in ing  regi­
m ens w ith  in c reased -c lo se  p ro to c o ls .  A lth o u g h  
m inor m odifications o f  the  s tandard  ch em o th er-
o r c isp la tin  200 m g /m 2 p e r  cycle. Overall, 84% of apy  reg im ens w ith  a 20%~50% increase in delivered
p a tie n ts  in th e  h ig h -d o se  arm  rece ived  80% or m o re  dose in tensity  are  n o t very likely to  im prove thera-
o f  th e  p ro je c te d  d o s e  o f  ch em o th e rap y , and  90% peu tic  ou tcom e, fu rther d o se  escala tions of 2-fold
o f  p a tie n ts  o n  the  s ta n d a rd -d o se  arm  rece ived  80% o r m o re  w ith  the  u se  o f  h e m a to p o ie tic  g ro w th
o r m o re  o f  the  p ro je c te d  dose . O f 76 e lig ible pa- factors p lus b o n e  m arro w  o r p e rip hera l stem  cell
tien ts  w h o  re c e iv e d  th e  h ig h -d o se  cisplatin  regi- su p p o rt  are new  an d  in teresting  ap p ro ach es , 
m en , 52(68% ) b e c a m e  d isease-free  w ith  c h e m o th e r­
ap y  a lo n e  o r  w ith  s u b s e q u e n t  resec tion  o f  residual
les ions, w h e re a s  o f  77  p a tien ts  w h o  rece ived  the High-dose chemotherapy in relapsed
s ta n d a rd  reg im e n , 56 (73%) b ecam e  d isease-free . patients and up-front high-dose chemotherapy
After a m e d ia n  fo llo w -u p  o f  24 m o n th s  63% o f in poor-risk patients 
p a tie n ts  in th e  h ig h -d o s e  cisplatin  arm  a n d  61%) in
th e  s ta n d a rd -d o s e  a rm  w ere  c o n tin u o u s ly  d isease- T he n ew  m eans o f c ircum ven ting  hem ato log ical
free. U n ivaria te  log istic  reg ress io n  analyses  investi- toxicity w ith the use  o f  au to lo g o u s  b o n e  m arrow
g ating  th e  re la t io n sh ip  b e tw e e n  d o se  in tensity  and  and  p e rip h e ra l s tem  cell su p p o rt  have p rov ided
o u tc o m e  w e re  u n a b le  to  c o n c lu d e  th a t c isplatin  o p p o rtu n itie s  for testing  significantly m ore  inten-
d o se  in ten s ity  h a d  a n  effect o n  response : c isplatin  sive trea tm en t reg im ens. Initial s tud ies w ere  carried
p  = 0*42, c isp la tin  a n d  e to p o s id e  p  = 0.33, the th ree  
d ru g s  p  « 0.15. T h e re fo re ,  co m p ariso n  o f  the single 
v a r iab le  o f  d o u b le -d o s e  c isp la tin  w ith  th e  s tan d ard  
d o se  as th e  co n tro l a rm  sh o w e d  that the in tensified  
c isp la tin  re g im e n  d id  n o t  transla te  into im proved  
surv ival o r  cu re . It s h o u ld  be n o te d  that the  n u m b e r
o u t in pa tien ts  failing seco n d -  or th ird-line o r  even 
m ultip le  p la tin um -co n ta in in g  reg im en s /11 The cure 
o f  10% - 20% of th ese  pa tien ts , in severa l cases 
overtly c isp la tin -refrac to ry  at conven tiona l doses, 
clearly su p p o rts  the clinical re levance  of a d o s e -  
re sp o n se  re la tionsh ip  in this d isease  w h e n  the dose 
o f  p a tie n ts  e n te re d  in to  this trial is too  lo w  to s ta te  of ch em o th erap y  can  be  substantia lly  au gm en ted .
tha t e q u iv a le n c e  h as  b e e n  sh o w n  b e y o n d  doub t. 
B es id es  c isp la t in , in c re a se d  d o sag es  of o th e r
Initial investigations used  h igh -dose  carbop la tin  
(900-2000  m g /m 2) and h igh-dose  e to p o s id e  ( 1.2 g /  
ag en ts  h av e  b e e n  in c o rp o ra te d  into ch e m o th e ra p y  m 2), tw o  courses, w ith  au to lo g o u s  b o n e  m arrow
p ro to c o ls .  S ince e to p o s id e  a n d  ifosfam ide are the 
tw o  m o st ac tive  s in g le  agen ts  apart from  cisplatin, 
and  the  th re e -d ru g  c o m b in a tio n  of c isplatin , e to p o -
support. S u b seq u en t s tud ies  inco rpo ra ted  ifosfa­
m ide (6-10  g /m 2) or cy c lo p h o sp h am id e  ( 2-6  g /m 2) 
in this c o m b in a tio n .*11“'18 From  these  stud ies it was
side, ifo sfam id e  (PEI) h ad  sh o w n  an efficacy in clear tha t d u rab le  rem issions are rarely o b ta in ed  in
re la p se d  p a t ie n ts ,39 fu r th e r  e x p lo ra tio n  w as w ar- patien ts  w ho  are refractory  to co n v en tio n a l-d o se
ran ted . T h e  G e rm a n  T es ticu la r  C ancer Study G roup  chem o th erap y . Refractory m eans p rogressive  dis-
has p e r fo rm e d  p h a s e  I/II d o se -esca la tio n  s tud ies  o f  ease  du ring  s tand ard  trea tm ent. Furtherm ore , 1()%~
PEI w ith  the  a d d it io n  o f  g ran u lo cy te  m acro p h ag e -  20% therapy -re la ted  d ea th s  w ere  ob se rv ed  in this
co lo n y  s t im u la tin g  fac to r  (GM-CSF), an d  su b se -  p re trea ted  g roup  o f  patien ts . Further s tud ies have
q u e n tly  s tu d ie s  w ith  th e  su p p o r t  of G-CSF an d  focused on th eea r lie ru til iz a tio n o fli ig li-d o sech em o -
a u to lo g o u s  p e r ip h e ra l  s tem  cells, as first-line ther- therapy , i.e. in first line or at first re lapse  after
ap y  for p o o r -p ro g n o s is  p a t ie n ts .“10 W ith o u t the use a d e q u a te  first-line therapy .
o f a h e m a to p o ie t ic  g ro w th  fac to r it a p p e a re d  that ^to
c isp la tin  25 m g / n r ,  e to p o s id e  '120-150 m g /m 2 and  
ifo sfam ide  1.2 g /m 2 e a c h  g iven  days 1—5 every  3
These efforts have in c lu d ed  using  au to logous  
b o n e  m arrow , a co m b in a tio n  of b o n e  m arrow  and 
au to logous p e riph era l stem  cells o b ta in ed  by leuka-
w e e k s  w as  th e  m a x im u m  to le ra ted  do se  schedu le , pheresis , and  p e r ip h e ra l stem  cells only. Both single 
w ith  m y e lo s u p p r e s s io n  b e in g  the  d o se - lim itin g  and  d o u b le  transp lan ts  have  b een  ap p lied  as initial 
toxicity . T h e  u se  o f  GM-CSF a llow ed  a m o d era te  salvage trea tm ent (u p o n  first re lapse) and  as consol-
in c rea se  in th e  d o s e  in tensity  o f  the sch ed u le  of 1.37 
(c isp la t in  30 m g /m 2, e to p o s id e  200 m g /m 2 a n d
ifo sfam ide  1.6 g /m 2, d ay s  1-5 every  3 w eeks). D ose-
idation  th e rap y  fo r p a tien ts  e ith e r  in co m p le te ly  
re sp o n d in g  to first-line co n v en tio n a l the rapy  or at 
h igh  risk of trea tm en t fa ilu re .‘,2",(v|(>
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High-close c h e m o th e ra p y  as part o f initial sal- b a se d  on  an  in a p p ro p r ia te  s low  d ec lin e  o f  se rum  
vage ch e m o th e ra p y  has b e e n  repo rted  on for 21 tu m o r m arkers  a fte r tw o  cycles o f  VAB-6 th e rap y / 6
and w ere  se le c te d  for tw o  cycles o f  h igh -d o se  th e r­
apy, 12 a ch iev ed  a c o m p le te  re sp o n se ,  11 o f  these 
rem ain ing  d isease -free  at a m e d ia n  fo llow -up  of 31 
m o n ths . O n e  p a tie n t  d ie d  from  trea tm en t-re la ted  
com plica tions. Toxicity  w as  n o t cum ula tive , and  
w ith  th e  ad d itio n  o f  G-CSF fo llow ing  b o n e  m arrow  
re infusion  reco v ery  o f  b lo o d  cou n ts  w as generally  
rap id . A lth o u g h  th e  p red ic tiv e  v a lu e  o f  increased  
m ark e r  half-lives (and  thus  the  ra tio n a le  to p ro c e e d  
to  h ig h -d o se  c h e m o th e ra p y  ) rem ain s  to  be fu rther
/ l th is s tu d y  ag a in  sh o w s that early  in ter­
v e n tio n  w ith tw o  cycles o f  h ig h -d o se  c h e m o th e ra p y  
is g enera lly  w ell to le ra ted  in this p a tie n t  g roup . 
B ased  o n  th e ir  e x p e r ie n c e  w ith  d o se -e sca la ted
patien ts w ith  p o o r-p ro g n o s is  germ  cell can cer (6 in ­
com ple te  re sp o n d e rs  to initial induc tion  therapy , 
and  '15 w ith  recu rren t d is e a se ).30 T hese  pa tien ts  
w ere trea ted  w ith  a reg im en  of e ither carbop la tin  
1200 m g /m 2, e to p o s id e  3.0 g /m 2 an d  ifosfam ide 6.0 
g /m 2, or ca rb o p la tin  800 m g /m 2, e to p o s id e  2.4 g /m 2 
and cy c lo p h o sp h a m id e  7.2 g /m 2, fo llow ed by in fu ­
sion of p rev iously  s to red  au to lo go u s  m arrow . T w o 
patients d ied  o f  trea tm en t-re la ted  toxicity, O nly  o n e  
of the 17 p a tien ts  w h o  w ere  au tografted  p ro g ressed  
desp ite  an initial favorable  re sp o n se  as reflected in 
m arker decline . F o u rteen  pa tien ts  rem ained  w ell 
and free after a m e d ia n  fo llow -up  of 3.3 years p o s t­
b o n e  m arrow  tran sp lan ta tio n  (DFS 67%).
In a n o th e r  s tu d y  18 o u t of 23 patien ts  in first re- PEI th e ra p y  the  G e rm an  T esticu lar C ancer Study
lapse received  tw o  cycles o f  conven tiona l c isp latin- G ro u p  has in c o rp o ra te d  the  se p a ra t io n  and  reinfu-
b ased  th e rap y , fo llo w e d  by a sing le  h ig h -d o se  sion o f  p e r ip h e ra l s tem  cells in ad d itio n  to hem ato -
reg im en o f ca rb o p la tin  1500-2100 m g /m 2 an d  e to p -  po ie tic  g ro w th  factor s u p p o r t  in to  th e ir  trea tm en t
oside 1200-2250 m g /m 2 w ith  au to lo go u s  b o n e  m ar- c o n c e p t  o f  u p -fro n t d o se - in ten s if ied  PEI ch em o -
row  s u p p o r t .44 This re su lted  in 11 co m p le te  rem is- t h e r a p y / 2,5*^ H e m a to p o ie tic  s tem  cells c an  easily be
sions, in c lu d in g  o n e  p a tien t w h o  w as re n d e re d  o b ta in ed  by le u k a p h e re s is  after s tim u la tion  w ith  G-
d isease-free  w ith  add itiona l surgery, and  5 w h o  o b or GM-CSF d u r in g  the  reco v e ry  o f  the  b o n e  m arro w
ta ined  partia l rem iss ion  for an  overall re sp o n se  ra te  fo llow ing  c h e m o th e ra p y , resu ltin g  in the  o p p o r tu -  
of 88%. The re sp o n se  rate of all pa tien ts  en tering  the  nity o f  h a rv es tin g  s tem  cells for su b se q u e n t  a u to ­
pro toco l w as  72%. T h ere  w as on ly  o n e  trea tm en t-  
re lated  dea th  in this cohort. O f those  com p le tin g  
h igh-dose  therapy , 7 o f  18 (39%) survived p ro g re s ­
sion-free w ith  a m ed ian  fo llow -up  of 26 m onths, 
Siegert et al. have  rep o rted  the  results o f  high- 
dose  ca rbop la tin , e to p o s id e  an d  ifosfam ide in pa-
logous  s tem  cell s u p p o r t  du rin g  repe titive  cycles o f  
h ig h -d o se  c h e m o th e ra p y . W ith this a p p ro a c h  m u l­
tiple cycles o f  c o n s id e rab ly  d o se -in ten s if ied  c h e m o ­
th e rap y  at 3- o r  4 -w eek  in tervals can  b e  de livered , 
w h ich — espec ia lly  in the  se ttin g  o f  sa lvage c h e m o ­
th e ra p y — m ay be  m ore  a ttrac tive  than  co n v en tio n a l
tients w ith  recu rren t germ  cell can ce r  follow ing a re in d u c tio n  fo llo w ed  by o n e  o r  tw o  h ig h -d o se
m edian  of six cycles o f  d sp la t in -b a se d  ch em o th e r-  co u rses . N o tab ly , in se v e ra l  p a t ie n ts  tre a ted  at
a p y / 1 Patien ts w e re  g iven  tw o induc tion  courses  o f  Ind iana  U niversity  it w as s h o w n  that d isease-free
conven tiona l PEI p r io r  to receiv ing  esca la ted  ther- s ta tus  w as o b ta in e d  o n ly  a fte r  th e  seco n d  cycle o f
apy. Seventy-four p a tien ts  rece iv ed  h igh -dose  ther- h igh -dose  c h e m o th e ra p y .*12 H ow ever, o n ce  op tim al
apy  consisting  o f ca rb o p la tin  1500-2000 m g /m 2, d o se -e sca la ted  reg im ens are  e s tab lish ed , the  true
e to p o s id e  1.2- 2 .4 g /m 2 and  ifosfam ide 0 -1 0  g /m 2. value o f  this a p p ro a c h  has  to b e  d e m o n s tra te d  in
Tw o pa tien ts  d ied  o f  trea tm en t-re la ted  toxicity. O f  p ro sp ec tiv e  ra n d o m iz e d  trials.
45 patien ts  w h o  re sp o n d e d  to induc tion  therapy , 24 O n e  such  s tu d y  has recen tly  b e e n  co m p le ted .
(.53%) w ere  d isease -free  w ith a p robab ility  o f  DPS at The add ition  o f  h ig h -d o se  c h e m o th e ra p y  to  con-
2 years of 50% (SD 8%)). v en tio n a l-d o se  induc tion  th e ra p y  for p a tien ts  with
Also at MSKCC, it w as d em o n stra ted  tha t h igh- un trea ted  p o o r-r isk  g e rm  cell can ce r  w as  c o m p a re d
dose c h e m o th e ra p y  as first sa lvage or part o f  the ini- w ith a s tan d a rd  re g im e n / 4 T he h ig h -d o se  reg im en
tial trea tm ent in se lec ted  pa tien ts  is be tte r  to le ra ted . was b ased  o n  th e ir  initial e x p e r ie n c e  w ith  a sa lvage
O f 13 pa tien ts  w h o  had  re lapsed  or incom ple te ly  reg im en  o f c isp la tin  200 m g /m 2 o v e r  5 days, etc)po­
res p o n d ed  to  c isp la tin  + ifosfam ide based  c h e m o ­
therapy, 6 o b ta in ed  an  as yet co m p le te  re sp o n se  
follow ing tw o  cycles o f  h ig h -d o se  carbop la tin  an d  
e toposide , w ith  3 d u ra b le  re sp o n ses  at 8+, 20+ and  
24+ m on ths  fo llo w -u p .4S O n e  pa tien t d ied  o f  trea t­
m ent-re la ted  toxicity. O f 22 patien ts  w h o  w ere  c o n ­
sidered  failures on  co n v en tio n a l (VAB-6 ) therapy ,
s ide  1.75 g /m 2 o v e r  5 days an d  c y c lo p h o sp h a m id e  
6.4 g /m 2 o v e r  4 days (P E C ) / '’ A total o f  115 p a tien ts  
w e re  ra n d o m iz e d  to  e i th e r  th ree  o r  fo u r  c o n v e n ­
tional (PVeBV: c isp la tin , v in b la s tin e , e to p o s id e , 
b leo m y c in )  cycles  o r  tw o  PVeBV cycles fo llow ed  by 
one  PEC cycle  w ith  a u to lo g o u s  b o n e  m arrow  s u p ­
port. The 2 -year survival w as  82% in the s tan d a rd
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arm, w h e re a s  it w a s  on ly  60% in th e  ex p erim en ta l 
arm. This d iffe ren ce  w as  n o t  statistically  significant, 
th o u g h  th e  p o w e r  o f  this trial to d e tec t d iffe rences 
w as lim ited  in v iew  o f  th e  n u m b e r  of pa tien ts  trea t­
ed. It is h o w e v e r  un like ly  that a benefit will be 
d e te c te d  in v iew  o f  the  d a ta  p re sen ted . Several a s ­
p ec ts  o f  this trial w a rran t d iscussion . T he p a tien ts  
on  the  h ig h -d o se  arm  received  an eq u iv a len t or 
lo w e r  to ta l d o s e  o f  c isp la tin  th a n  the  p a t ie n ts  
tre a ted  w ith  th ree  o r  fou r cycles o f  PVeBV. C arbo ­
p la t in  w o u ld  p e rm it  a s u b s ta n t ia l  h ig h e r  to ta l 
‘platinum* d o se  ( 1500-2000  m g /m 2) in  v iew  o f the 
relative lack  o f  n o n -h em a to lo g ic  toxicity  o f  c a rb o ­
p la tin , a n d  sh o u ld  be  co n s id e red  first ch o ice  high- 
d o se  c h e m o th e ra p y ,
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It is feasib le  to in c re a se  th e  d o se  in tensity  w h e n  
h e m a to p o ie tic  g ro w th  factors are used. It is h o w ­
ev e r  q u e s t io n a b le  w h e th e r  im proved  efficacy can  
b e  o b ta in e d  w ith  the  m o d estly  in c rea sed  d o se s  o r 
sh o r te n e d  in terval w h ic h  can  be  ob ta ined . T he  use  
o f  h e m a to p o ie tic  g ro w th  factors w ith o u t o th er form s 
o f s u p p o r t  can  resu lt in a 20%-5Q% d o se  in tensifi­
cation. In  c o m b in a tio n  w ith  e ither au to lo g o u s  b o n e  
m a rro w  o r p e r ip h e ra l  stem  cells it has clearly  b e e n  
sh o w n  tha t a d e q u a te  d o se s  o f  ch e m o th e ra p y  can  be  
g iven  w h ich  m ay o v e rc o m e  'c h e m o th e ra p y  resist­
ance* in p a tien ts  w ith  a d v a n c e d  o r re lapsing  germ  
cell tum ors. This has  n o w  resu lted  in DFS ra tes 
h ig h e r  th an  can  b e  e x p e c te d  w h en  using  c o n v e n ­
tional c isp la tin -b ased  c h e m o th e ra p y »56,57 m o reo v e r  
w ith  a c c e p ta b le  toxicity. Also, in se lec ted  cases of 
p a tien ts  w ith  m ultip le  p o o r-p ro g n o s is  factors w ith  
p red ic ted  survival rates o f  < 50% w h e n  using  c o n ­
v en tion a l reg im ens, th e  c o n c e p t of h ig h -d o se  th e r­
apy  sh o u ld  b e  fu rth e r  ex p lo red . For true resistan t 
pa tien ts , as d e f in e d  earlier, it is obv ious tha t only  
a b o u t 10% of p a tien ts  w ill o b ta in  a du rab le  d isease- 
free sta tus and  th e se  a re  n o t a p p ro p ria te  cand ida tes  
for fu rther e x p lo ra tio n  o f  this ap p ro ach .
As has  b e e n  m e n tio n e d , the true  value o f  optim al 
d o se -e sca la ted  reg im en s  has to be d em o n s tra ted  in 
p ro sp ec tiv e  ra n d o m iz e d  trials. T he relative rarity of 
p a tie n ts  re la p s in g  a f te r  m o d e rn  c isp la t in -b a se d  
c h e m o th e ra p y  as w ell as pa tien ts  p resen tin g  w ith  
m ultip le  p o o r-p ro g n o s tic  fea tu res  will com plica te  
such clinical investiga tions. Since survival d iffer­
ences  o f  m o re  th a n  20% are  n o t to be  ex p ec ted , such  
trials w ill re q u ire  sev e ra l h u n d re d s  of p a tien ts , 
w hich  e v e n  in the  case  o f  co llaborative  efforts will 
lead  to trial d u ra tio n s  o f  at least 5 o r 6 years.
1. Einhorn LH, Donohue JP. Cis-diamminodichloroplatinum, 
vinblastine, and bleomycin combination chemotherapy in 
disseminated testicular cancer. A n n  Inter Med  1977; 87: 
293-298.
2. Hutter H, Motzer R, Schwartz L, etal. Phase U trial of Taxol 
in cisplatin-resistant germ cell tumor (GCT) patients (PTS). 
Proc A m  Soc Clin Oncol 1994; 13: 232 (Abstract 712).
3. Einhorn LH. Chemotherapy of disseminated germ cell 
tumors. Cancer 1987; 60: 570-573.
4. Einhorn LI-1, Williams SD, Chemotherapy of disseminated 
testicular cancer. Cancer 1980; 46: 1339-1344.
5. Einhorn LH, Williams SD, Trôner M, et a l  The role of 
m aintenance therapy in disseminated testicular cancer. N
B u g /J  M ed m u  305: 727-731,
6. Einhorn LH. Treatment of testicular cancer: a new and 
improved model. J  Clin Oncol 1990; 8; 1777-1781,
7. Dearnaley DP, Horwich A, ATIern R, et ciL Combination 
chem otherapy with bleomycin, etoposide and cisplatin 
(BEP) for metastastic testicular teratoma: long-term fol­
io w-u p . U u rj Ca n car 1991; 27; 684-691.
S. Stoter G, Ko o pman A, Vend ri k CPJ, et al. Te n- y ea r s u rv i v a l 
and late sequelae in testicular cancer patients treated with 
cisplatin, vinblastine, and bleomycin. J  Clin Oncol 1989; 7: 
1099-1104.
9. Bajorin D, Katz A, Chan E, Geller N, Vogelzang N, Bosl GJ, 
Com parison of criteria for assigning germ cell tumor pa­
tients to “good risk" and “poor risk" studies, J  Clin Oncol 
1988; 6: 786-792.
10. Birch R, Williams S, Cone A, et al. for the Southeastern 
Cancer Study Group. Prognostic factors for favorable out­
com e in disseminated germ cell tumors. J  Clin Oncol 1986;
4: 400-407.
11. Bosl GJ, Geiler NL, Cirrincione C, et a i  Multivariate ana­
lysis of prognostic variables in patients with metastatic 
testicular cancer. Cancer Res 1983; 43: 3403-3407.
12. Mead GM, Stenning SP, Parkinson MC, et al. for the Med­
ical Research Council Testicular Tumour Working Party. 
The second Medical Research Council study of prognostic 
factors in nonseminomatous germ cell tumors, J  Clin 
Oncol .1992; 10: 85-94.
13. Medical Research Council. Working Party report on tes­
ticular tumours. Prognostic factors in advanced non 
seminoma to vis germ cell testicular tumours: results of a 
m u 11 ice n tre s tu dy. La n cet 1985; i : 8-11.
14. Stoter G, Sylvester R, Sleijfer DT, et al. Multivariate anal­
ysis of prognostic variables in patients with dissemina­
ted non-semi noma to us testicular cancer: results from an 
EORTC multi-institutional study. Cancer Res 1987; 47: 
2714-2718.
15. Stoter G, Bosl GJ, DroxJP* et a i  Prognostic factors in meta­
static germ cell tumors, In: Ncwling DWW, Jones WG, eds. 
Prostate Cancer a n d  Testicular Cancer. New York: Wiley- 
Liss Inc. 1990; 357, 313-319.
16. Hryniuk WM. The importance of dose intensity in the 
outcom e of chemotherapy. In: I)e Vita VT, Heilman S, 
Rosenberg SA, eds. Important Advances in Oncology* 
Philadelphia, PA: Lippincott 1988; 121-124.
17. Garrow GC, Johnson DH. Treatment of "good risk" meta­
static testicular cancer. Sent Oncol 1992; 19: 159-165.
18. Loehrer PJ, Johnson D, Elson P, Einhorn LH, Trump D. 
Im portance of bleomycin in favorablc-prognosis dis­
sem inated germ  cell tumors: an Has tern Cooperative 
Oncology Group trial, y Clin Oncol 1995; 13: *170-476.
50 Anti-Cancer Drugs * Vol 6, Suppl 5 ■ 1995
19. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation 
of optimal duration of chem otherapy in favorable-prog- 
nosiic disseminated germ cell tumors: a Southeastern 
Cancer Study Group pro toco l /  Clin Oncol 1989; 7: 387-
391.
20. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial 
of etoposide and cisplatin versus etoposide and carboplatin 
in patients with good-risk germ  cell tumors: a multi- 
institutional study. J  Clin Oncol 1993; IX: 598-606,
21. Horwich A, Sleijfer D, Fossa S, et al. on behalf of the UK 
Medical Research Council Testicular Tum our Working 
Party & EORTC Genito-Urinary Group. Atrial of carbopl at in­
based combination chem otherapy in good  prognosis 
metastatic testicular non-seminoma, Proc ASCO 1994;
13: 231.
22. Williams SD, Birch R, Einhorn LH, etal. Treatment of dis­
seminated germ cell tumors with cisplatin, bleomycin and 
either vinblastine or etoposide, N  Engl J  Med 1987; 316: 
1435-1440.
23. Motzer RJ, Geller NL, Bosl GJ. The effect of a 7-day delay 
in chemotherapy cycles on com plete response and event- 
free survival in good-risk disseminated germ cell tum or 
patients. Cancer 1990; 66: 857-86'1.
24 Goldie JH, Goldman AJ, Guclauskas GA. Rationale for the 
use of alternating non-cross-resistant chemotherapy. Can­
cer Treat Rep 1982; 66: 439-449,
25. Goldie JH, Goldman AJ, The genetic origin of drug res­
istance in neoplasms: implications for systemic therapy.
Cancer Res 1984; 44: 3643-3653.
26. Hitchins RN, Newlands ES, Smith DB, Begent RHJ, Rustin 
GJS, Bagshawe KD. Long-term outcom e in patients with 
germ cell tumours treated with POMB/ACE chemotherapy: 
com parison of commonly used  classification systems 
of good and poor prognosis. B r J  Cancer 1989; 59; 236- 
242.
27. Cullen MH, Harper PG, Woodroffe CM, Kirkbride P, Clarke 
J. Chemotherapy for poor risk germ cell tumours. An 
independent evaluation of the POMB/ACE regime. B r J  
Urol 1988; 62: 454-460.
28. Logothetis CJ, Samuels ML, Selig DE, et al. Cyclic chem o­
therapy with cyclophosphamide, doxorubicin, and cispla­
tin plus vinblastine and bleomycin in germinal tumors —  
Results with 100 patients. A m  J  M ed  1986; 81; 219-228.
29. Bosl GJ, Geller NL, Vogelzang NJ, et aL Alternating cycles 
of etoposide plus cisplatin and VAB-6 in the treatment of 
poor-risk patients with germ cell tumors, ƒ  Clin Oncol 
1987; 5: 436-440.
30. Wit de R, Stoter G, Sleijfer DTh, et at. Four cycles of BEP 
versus an alternating regime of PVB and BEP in patients 
with poor-prognosis metastatic testicular non-seminoma; 
a randomised study of the EORTC Genitourinary Tract 
C a n c e r C o ope ra t i ve G ro up, B r J  Cancer 1995; 71 ; 1311- 
1314.
31. Kaye SB, Mead GM» Fossa S, Cullen M, Wit de R, Boclrogi 
I, Groeningen van C, Sylvester R, Stenning S, Vermeylen 
K, Lallemand E, Mulder de PHM. An MRC/EORTC ran­
domised trial in poor prognosis metastatic teratoma, com­
paring BEP with BOP-VÏP. Proc ASCO  1995; 14: 246.
32. Lewis CR, Fossa SD, Mead G, et aL BOP/VIP —  A new  
platinum-intensive chemotherapy regimen for poor prog­
nosis germ cell tumours. A nn  Oncol 1991; 2: 203-211,
33. Fossa S, Kaye SB, Mead GM, Cullen M, Wit de R, Bodrogi 
I, Groeningen van C, Sylvester R, Stenning S, Vermeylen 
K, Lallemand E, Mulder de PHM. An MRC/EORTC ran­
domised trial in poor prognosis metastatic teratoma com­
paring treatment with/without filgrastim (G-CSF). Proc 
ASCO 1995; 14: 245.
34. Pastan I, Gottesnvan M. Mukiple-drug resistance in human 
cancer. N  Engl J  Med 1987; 316: 1388-1391.
35. Sampson MK, Rivkin SE, Jones SE, et aL Dose response 
and dose-su rvival adavantage for high versus low cisplatin 
com bined with vinblastine and bleomycin in disseminated 
testicular cancer. A Southwest Oncology Group Study.
Cancer 1984; 53; 1029-1035.
36. Ozols RF, 111 de DC, Lin chan WM, Jacob J, Ostehega Y, 
Young RC. A randomized trial of standard chemotherapy 
V a high-dose chemotherapy regimen in the treatment of 
poor prognosis nonseminomatous germ-cell tumors. J  
Clin Oncol 1988; 6: 1031-1040,
37. Daugaard G, Rorth M, High-dose cisplatin and VP-16 with 
bleomycin, in the management of advanced metastatic 
ge rm cell tunic > rs. Eu t * J  Ca neer 1986; 22: 477-48 5.
38. Nichols CR, Williams SD, Loehrer PJ, et ai. Randomized 
study o f cisplatin dose intensity in poor-risk germ cell 
tumors: u Southeastern Cancer Study Group and South­
west Oncology Group protocol. J  Clin Oncol 1991; 9: 
1163-U72.
39. Loehrer PJ, Einhorn LH, Williams SD. VP-16 plus ifosfamide 
plus cisplatin as salvage therapy in refractory germ cell 
cancer, ƒ  Clin Oncol 1986; 4: 528-536.
40. Bokemeyer C, Schmoll HJ, Harstrick A, et al. A phase I/M 
study of a stepwise dose-escalated regimen of cisplatin, 
e toposide and ifosfamide plus granulocyte-macrophage 
colony-stimulating factor(GM-CSF) in patients with advan­
ced germ cell tumours, E urJ Cancer 1993; 29A: 2225-31.
41. Nichols CR, Tricot G, Williams SD, et al. Dose-intensive 
chem otherapy in refractory germ cell cancer— A phase 1/
II trial of high-dose carboplatin and etoposide with autol­
ogous bone marrow transplantation. JC lin  Oncol 1989; 7:
932-939.
42. Broun ER, Nichols CR, Kneebone P, et al. Long-term out­
com e of patients with relapsed and refractory germ cell 
tumors treated with high-dose chemotherapy and auto­
logous hone marrow rescue. A nn  Inter Mod 1992; 117: 
124-128.
43. Nichols CR, Andersen J, Lazarus HM, et al. High-dose 
carboplatin and etoposide with autologous bone marrow 
transplantation in refractory germ cell cancer: an Eastern 
Cooperative Oncology Group P ro to co l./Clin Oncol 1992;
10: 558-563.
44. Broun ER, Nichols CR, Turns M, etal. Early salvage therapy 
for germ cell cancer using high dose chemotherapy with 
autologous bone marrow support. Cancer 1994; 73:1716- 
1720.
45. Motzer RJt Gulati SC, Crown J l \  et a i  High-dose chemother­
apy and autologous hone marrow rescue for patients with 
refractory germ cell tumors, Cancer 1992; 69: 550--556.
46. Motzer RJ, Mazumdar M, Gulati SC, et a l  Phase II Irial of 
high-dose carboplatin and etoposide wiili autologous 
bone marrow transplantation in first-line therapy lor pa­
tients with poor-risk germ cell tumors. J  Natl Cancer Inst
1993; 85: 1828-1835.
47. DrozJP, Pico JL, Ghosn M, et a l  Long-term survivors after 
salvage high dose chemotherapy with bone marrow res­
cue in refractory germ cell cancer. EurJ Cancer 1991; 27: 
831-835.
48. Linkesch W, Krainer M, W agner A. Phase I/II trial of ultra- 
high carboplatin, etoposide, cyclophosphamide with ABMT 
in refractory or relapsed non-sc mi noma tous germ cell 
turn o rs. Ik) n  e Marrow  7 'ramp11992; 10 ( S u p pi 2 ) : 28-2 9.
Anti-Cancer Drugs • Vol 6, Suppl 5 * 799.5 51
PHM De M ulder a n d  R de Wit
49. Rosti G, Alberta?,zi L, Salvioni R, et a l  High-close chem o­
therapy supported  with autologous bone marrow trans­
plantation (ABMT) In germ cell tumors: a phase II study. 
A n n  Oncol 1992; 3: 809-812.
50. Barnett MJ, C oppin  CML, Murray N, et a l  High-dose 
chem otherapy and  autologous bone marrow transplanta­
tion for patients with poor prognosis nonsem inom atous 
germ cell tumours. B r J  Cancer 1993; 68: 594-598.
51. Siegert W, Beyer J, Strohscheer I, et a l  High-dose treat­
m ent w ith carboplatin, etoposide, and ifosfamide follow­
ed  by auto logous stem-cell transplantation in relapsed or 
refractory germ cell cancer: a phase I/II study. JC lin  Oncol 
1994; 12: 1223-1231.
52. Stevens MJ, N orm an AR, Dearnaley OP, Horwich A. Prog- 
nostlcsignificance o f early serum tumor marker half-life in 
metastatic testicular terato ma. J  CUnOncol 1995; 13:87-92.
53ï Bokemeyer C, Schmoll HJ. Treatment of advanced germ 
cell tum ours by dose  intensified chem otherapy  with
haem atopoietic growth factors or peripheral blood stem 
cells (PBSC). Bur Urol 1993; 23: 223-230.
54. Bokemeyer C, Beyer J, Schmoll HJ. The role of dose- 
intensified chem otherapy for the treatment of metastatic 
germ cell tumours. 7rends Exp Clin Med 1994; 4: 671- 
680.
55. Chevreau C, Dvoz JP, Pico JL, et al. Early intensified 
chem otherapy with autologous bone marrow transplanta­
tion in first line treatment of poor risk non-seminoma to us 
germ cell tumours. Eiir Urol 1993; 23: 213-218.
56. Bosl GJ, Yagoda A, Golbey RB, et a l  Role of etoposide- 
based chem otherapy in the treatment o f  patients with 
refractory or relapsing germ cell tumors. Am J  Med 1985; 
7 8 :4 2 3 -4 ;
57. Motzer RJ, Bajorin DF, Vlamis V, Weisen S, Bosl GJ. 
Ifosfamide-based chem otherapy for patients with resistant 
germ cell tumors: the Memorial Sloan-Kottering Cancer 
C en ter Exp er i e n ce . Sem Oncol 1992; 19: 8-12.
52 Anti-Cancer Drugs * Vol 6, Suppl 5 * '1995
